Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Liver Int. 2011 May;31(5):700-6. (CUMC Full Text PDF).
The reported prevalence of NAFLD and NASH in type-2 diabetic patients with either ultrasonographic evidence of fatty liver or abnormal transaminase levels and negative work-up for other liver diseases was 94% and 78%, respectively. The authors suggest that liver biopsy should be considered for all type-2 diabetic patients in this setting.
Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Liver Int. 2011 May;31(5):700-6. (CUMC Full Text PDF).
The reported prevalence of NAFLD and NASH in type-2 diabetic patients with either ultrasonographic evidence of fatty liver or abnormal transaminase levels and negative work-up for other liver diseases was 94% and 78%, respectively. The authors suggest that liver biopsy should be considered for all type-2 diabetic patients in this setting.
No comments:
Post a Comment